# A Long-Term Follow-Up Study in Subjects Who Received vMCO-I Administered Via Intravitreal Injection

> **NCT05921162** · — · ENROLLING_BY_INVITATION · sponsor: **Nanoscope Therapeutics Inc.** · enrollment: 11 (estimated)

## Conditions studied

- Retinitis Pigmentosa
- Retinal Disease
- Retinal Degeneration

## Interventions

- **BIOLOGICAL:** Gene Therapy product:vMCO-I

## Key facts

- **NCT ID:** NCT05921162
- **Lead sponsor:** Nanoscope Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2023-07-14
- **Primary completion:** 2025-05
- **Final completion:** 2025-05
- **Target enrollment:** 11 (ESTIMATED)
- **Last updated:** 2025-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05921162

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05921162, "A Long-Term Follow-Up Study in Subjects Who Received vMCO-I Administered Via Intravitreal Injection". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05921162. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*